A proposed strategy to cure HIV,known as ashock and killa,uses latency-reversing agents(LRAs)to reactivate latent proviruses for the purge of HIV reservoirs.A variety of small molecule LRAs have been identified,but none has yet been proven effective in actually reducing the reservoir size in vivo partially due to their low potency,poor solubility,and toxicity issues.Additionally,the diverse physicochemical properties of LRAs also limit their combination to achieve maximal latency reversal.Nanocarriers(NC)address these challenges by improving drug solubility,safety,and providing sustained drug release and simultaneous delivery of multiple drugs to target tissues and cells.
展开▼
